Comparison of Architect I 2000 for Determination of Cyclosporine with Axsym - Zdravlje, medicina, lijecenje, zdravstveni portal

Comparison of Architect I 2000 for Determination of Cyclosporine with Axsym

Comparison of Architect I 2000 for Determination of Cyclosporine with Axsym
Nafija Serdarevic, Lejla Zunic
Acta Inform Med. 2012; 20(4): 214-217

View PDF Fulltext


Background: Cyclosporine has been shown effective drug in suppressing acute rejection in recipients of allograft organ transplants. Methods: The cyclosporine concentration of 96 blood samples was determined using CMIA (chemiluminesecent microparticle immnoassay) Architect i 2000 and FPIA (fluorescence polarization immunoassay) AxSYM Abbott diagnostic. All patients have transplantation of kidneys and were hospitalized at Department of Nephrology at the Clinical center of University of Sarajevo. The reference serum range of cyclosporine for kidney organ transplantation for maintenance lies between 50 and 150 ng/mL. The quality control, precision and accurancy of Architect i 2000 were assessed. Results: The quality control was done using quality control serums for low (= 91 ng/mL), medium (= 328 ng/mL) and high (= 829 ng/mL). We have used commercial BIORAD controls and got reproducibility CV 5.83 % to 13 % for Architect i 2000. It was established that the main difference between Architect i 2000 and AxSYM and it was statistically significant for P < 0.05 according to Student t-test. Correlation coefficient was r = 0.903. Conclusion: The CMIA Architect assay has significant reduced cyclosporine metabolite interference relative to other immunoassay and is a convenient and sensitive automated method to measure cyclosporine in whole blood.


1. Yatscoff RW, Rosano TG, Bowers LD. The clinical significance of cyclosporin metabolites. Clin Biochem. 1991; 24: 23-35.

2. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther. 1993; 57: 291-345.

3. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A. Consensus Document: Hawks Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem. 1990; 36: 1510-1516.

4. Shaw LM, Yatscoff RW, Bowers LD, Freeman DJ, Jeffery JR, Keown PA, et al. Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem. 1990; 36: 1841-1846.

5. Morris RG, Tett SE, Ray JE. Cyclosporin A monitoring in Australia: consensus recommendations. Ther Drug Monit. 1994; 16: 570-576.

6. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993; 54: 205-218.

7. Johnston A, Sketris I, Marsden JT, Galustian CG, Fashola T, Taube D, et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc. 1990; 22: 1345-1346.

8. Grevel J, Kahan BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem. 1991; 37: 1905-1908.

9. Amante AJ, Kahan BD. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period. Clin Chem. 1996; 42: 1294-1296.

10. Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation. 1999; 67: 1133-1137.

11. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999; 68: 55-62.

12. Mahalati K, Lawen J, Kiberd B, Belitsky P. Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period?. J Urol. 2000; 163: 37-41.

13. Learning Guide: Immunoassay: Introduction to Immunoassays. Learning Objectives. After completion of this chapter, you will be able to: • define immunoassay, Abbottt (Accessed October 29, 2011)

14. Operator vs Manuel Cyclosporine ARCHITECT SYSTEM Abbott Diagnostic, REF 1L75 301-513 10/10 2004.

15. Operator vs Manuel Cyclosporine AxSYM SYSTEM Abbott Diagnostic, REF 8K/18 49-3305/R4 2004.

16. Holt DW, Johnston A, Marsden JT, Vernillet L, Keown PA, Rosano TG, et al. Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit. Clin Chem. 1988; 34: 1091-1096.

17. Wang CP, Burckart GJ, Ptachcinski RJ, Venkataramanan R, Schwinghammer T, Hakala T, et al. Cyclosporine metabolite concentrations in the blood of liver, heart, kidney, and bone marrow transplant patients. Transplant Proc. 1988; 20(Suppl 2): 591-596.

18. Lindholm A, Henricsson S. Simultaneous monitoring of cyclosporin in blood and plasma with four analytical methods: a clinical evaluation. Transplant Proc. 1989; 21: 1472-1474.

19. Holt DW, Marsden JT, Fashola TO, Johnston A. Performance of the Sandoz radioimmunoassays for cyclosporine. Transplant Proc. 1990; 22: 1155-1159.

20. Bowers LD. Therapeutic monitoring for cyclosporine: difficulties in establishing a therapeutic window. Clin Biochem. 1991; 24: 81-87.

21. Murthy JN, Yatscoff RW, Soldin SJ. Cyclosporine metabolite cross-reactivity in different cyclosporine assays. Clin Biochem. 1998 Apr; 31(3): 159-63.2002, Jul; 48(7): 1059-65.

22. Wallemacq P., Maine GT., Berg K., Rosiere T. at all. Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay. Ther Drug Monit. 2010 Apr;32(2): 145-151.

Leave a reply

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>